Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats.

The Journal of Pharmacology and Experimental Therapeutics
Akira NishiyamaMasahito Imanishi

Abstract

Treatment with angiotensin II type 1 receptor blockers (ARBs) is the first-line therapy for hypertensive patients with diabetic nephropathy. However, emerging clinical evidence indicates that mineralocorticoid receptor (MR) blockers have blood pressure-independent antiproteinuric effects. We sought to determine whether treatment with an MR blocker, eplerenone, enhances the effects of an ARB, telmisartan, on podocyte injury and proteinuria in type 2 diabetic Otsuka-Long-Evans-Tokushima-Fatty (OLETF) rats. From 20 to 50 weeks old, diabetic OLETF rats showed higher systolic blood pressure (SBP) and urinary protein excretion (U(protein)V) than nondiabetic control Long-Evans-Tokushima-Otsuka rats. At 50 weeks old, OLETF rats also showed glomerular sclerosis and podocyte injury, whereas nephrin and podocin mRNA levels in isolated glomeruli were significantly decreased. Treatment with telmisartan (3 mg/kg/day p.o.) decreased SBP and U(protein)V, increased nephrin and podocin mRNA levels, and attenuated glomerular sclerosis and podocyte injury. Eplerenone (100 mg/kg/day p.o.) did not alter SBP but elicited similar changes in renal parameters. However, greater reductions in U(protein)V and podocyte injury and greater increases in nephri...Continue Reading

References

Jul 9, 1998·The New England Journal of Medicine·P FiorettoM Mauer
Sep 22, 2001·The New England Journal of Medicine·A Chrysostomou, G Becker
Oct 19, 2001·Cardiovascular Drug Reviews·J A DelyaniB Whelihan
Jan 4, 2003·Hypertension·Atsuhisa SatoTakao Saruta
Jul 23, 2003·Journal of the American Society of Nephrology : JASN·Klaas KoopJan A Bruijn
Aug 29, 2003·American Journal of Hypertension·Atsuhisa Sato, Takao Saruta
May 20, 2004·Kidney International·Ariela BenigniGiuseppe Remuzzi
May 22, 2004·Journal of the American Society of Nephrology : JASN·Sigrid HoffmannNorbert Gretz
Jan 14, 2005·Journal of the American Society of Nephrology : JASN·Yukiko NagaiAkira Nishiyama
Feb 5, 2005·American Journal of Hypertension·Atsuhisa SatoTakao Saruta
May 13, 2005·Journal of the American Society of Nephrology : JASN·Hiroyuki KoboriAkira Nishiyama
Jul 5, 2005·The Journal of Steroid Biochemistry and Molecular Biology·Tetsuo NishikawaGeorge Chrousos
Jan 4, 2007·Hypertension·Shigeru ShibataToshiro Fujita
Jun 2, 2007·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Susumu OgawaSadayoshi Ito
Aug 31, 2007·Clinical and Experimental Hypertension : CHE·Firas YounisTalma Rosenthal
Jan 25, 2008·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Andrew S BombackPhilip J Klemmer
Apr 18, 2008·Kidney International·J A JeffersonR H Pichler
Aug 7, 2008·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Young Sun KangDae Ryong Cha
Dec 6, 2008·Journal of Pharmacological Sciences·Hideyasu KiyomotoAkira Nishiyama
Mar 21, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Toshio OgiharaUNKNOWN Japanese Society of Hypertension Committee

❮ Previous
Next ❯

Citations

Sep 22, 2012·Cell & Bioscience·Simran KhuranaHung-Ying Kao
Dec 27, 2012·Clinical and Experimental Nephrology·Fumihiro SugiyamaToshihiko Ishimitsu
Feb 18, 2011·The American Journal of the Medical Sciences·Hou-Yong DaiBi-Cheng Liu
Aug 9, 2011·Molecular and Cellular Endocrinology·Alex Odermatt, Denise V Kratschmar
Apr 14, 2015·Biochemical and Biophysical Research Communications·Motonobu NakamuraShoko Horita
Dec 28, 2010·Journal of Pharmacological Sciences·Kazi RafiqAkira Nishiyama
Mar 10, 2017·Expert Opinion on Investigational Drugs·Viviana LacavaDomenico Santoro
Sep 30, 2010·Journal of Cardiovascular Pharmacology and Therapeutics·Mohammad Abuannadi, James H O'Keefe
Jan 9, 2013·Nature Reviews. Nephrology·Miki Nagase, Toshiro Fujita
Apr 5, 2014·Journal of the American Society of Nephrology : JASN·Louis L HuangGreg H Tesch
Nov 3, 2011·Nature Reviews. Nephrology·Peter W Mathieson
May 17, 2013·International Heart Journal·Mayuko IshikawaToshihiko Ishimitsu
Jun 11, 2011·Ultrastructural Pathology·Sihem DarouichAdel Kheder
Mar 5, 2020·Journal of Veterinary Pharmacology and Therapeutics·Sarah SpencerJonathan Elliott
Sep 19, 2020·Nature Reviews. Nephrology·Shipra AgrawalPierre-Louis Tharaux
Nov 21, 2012·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Ryuichi NoguchiHiroshi Fukui
Nov 13, 2020·Drug Development Research·Vishal PatelMukul Jain
May 28, 2019·Kidney International·Jonatan Barrera-ChimalFrederic Jaisser

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.